Your daily source for trading strategies, tech news, and politically incorrect humor.
Hey there, Bullets Fans –
Your Morning Bullets Brief Updates are here! And that means trivia is, too.
Who is credited with the following piece of investing advice?
“Don’t look for the needle in the haystack. Just buy the haystack!”
Think you know the answer? You can check it in the closing area down below!
Image Source: Morning Bullets
The Dow Jones Industrial Average is poised for a 200-point gain this morning after the benchmark fell 0.5% yesterday. The Nasdaq and the S&P 500 also drifted downward on Tuesday, slipping 1.7% and 0.8%, respectively.
This morning ADP releases its latest look at private payrolls for the month of February. Analysts hope that the report reflects an additional 225,000 jobs. In January, that number came in at 174,000.
In Washington, meanwhile, the Senate is slated to begin debating its version of the House-approved massive virus relief bill. This iteration of the legislation will not include a federal minimum wage hike.
And President Joe Biden said yesterday that there will soon be enough vaccine doses for “every adult in America.” He anticipates reaching this milestone by the end of May. This announcement comes as the governors in both Texas and Mississippi are relaxing their virus restrictions.
In other news, big companies are pushing Congress to create a path toward citizenship for ‘dreamers.’
Other News That Matters To You:
If you miss this emerging megatrend, you just might regret it
Image Source: Reuters
The pandemic has brought an unprecedented partnership into the limelight. Former rivals Merck and Johnson & Johnson are working together to produce a new single-shot version of the vaccine.
“Extraordinary times take extraordinary efforts,” said Alex Gorsky, who is the CEO of Johnson & Johnson.
His company’s vaccine just received FDA clearance to distribute their one-dose drug that is 66% effective at keeping the virus at bay. Their vaccine is also 86% effective at keeping recipients from getting severely sick, and it was 100% effective at preventing deaths and hospitalizations, data shows.
Merck is apparently lending a couple of its facilities for the drug’s production.
“The real war here is against [the virus], and I couldn’t think of a better partner than Merck, a company with an incredibly strong reputation,” said Gorsky. “We think it’s going to add considerably to our capabilities both near and in the long term.”
More Headline You Need To Read: